Drugs /

ae37 peptide/gm-csf vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The Ii-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic.

Clinical Trials

View Clinical Trials for ae37 peptide/gm-csf vaccine

Ae37 peptide/gm-csf vaccine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating ae37 peptide/gm-csf vaccine, 1 is phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for ae37 peptide/gm-csf vaccine clinical trials.

Breast adenocarcinoma is the most common disease being investigated in ae37 peptide/gm-csf vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ae37 Peptide/gm-Csf Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ae37 peptide/gm-csf vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

NCIT ID [1]:
C91719

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.